Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation

Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation

Objectives: Real-world experience with coformulated bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) is sparse as a switch regimen among people living with HIV (PLWH) having achieved viral suppression after previous virologic failures with the emergence of K65N/R. Methods: In this...

Full description

Bibliographic Details
Main Authors: Mao-Song Tsai, Hsin-Yun Sun, Cheng-Pin Chen, Chen-Hsiang Lee, Chun-Yuan Lee, Chun-Eng Liu, Hung-Jen Tang, Tung-Che Hung, Chia-Wen Li, Yuan-Ti Lee, Bo-Huang Liou, Chia-Jui Yang, Chien-Ching Hung
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:International Journal of Infectious Diseases
Subjects:
Viral rebound
Low-level viremia
Integrase strand-transfer inhibitor
Nucleoside reverse-transcriptase inhibitor
Resistance-associated mutation
Genetic barrier
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971222005975

Internet

http://www.sciencedirect.com/science/article/pii/S1201971222005975

Similar Items